CA-LIQUID-INSTRUMENTS
23.3.2021 14:02:04 CET | Business Wire | Press release
Today, Liquid Instruments , an innovator in precision software-defined instrumentation, launched Moku:Go , a complete, portable platform designed to bring the engineering lab anywhere and usher in a new era of scientific and engineering education at universities around the world.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210323005031/en/
Within higher education, current in-person lab instrumentation is stationary, expensive, hardware-limited and fixed at the time of purchase. Existing portable solutions lack the intuitive software interfaces that current and future generations of students have come to expect. They also do not offer all of the necessary instruments and features to enable students to learn effectively outside of the lab. The increasing demand for remote learning solutions and a more hands-on experience both in and out of the classroom has fueled the market need for student-owned, flexible platforms that can support the next generation of engineers and scientists.
The new software-enabled hardware platform, Moku:Go, is an engineering lab that can fit in a backpack. It was designed for maximum portability, flexibility and durability, to take not just electrical engineering students, but physics, bioengineering, chemical engineering and other majors through all four years of their education and even beyond. It starts with 8 proven, powerful instruments including an oscilloscope, PID controller, logic analyzer, arbitrary waveform generator, data logger, spectrum analyzer, and more. It also features full connectivity with a Wi-Fi hotspot and USB-C, robust hardware features and electrical protection to ensure that students can explore new projects without putting themselves or their equipment at risk. The unique integrated power supplies are user programmable with high voltage and high current options for any project.
“Our students were thrilled when we first added Moku:Lab to our classroom two years ago, and after seeing the new capabilities of Moku:Go, I’m even more excited. It is clear that it will help take students’ educational experience into the modern era,” said Colonel Brian J. Neff, Electrical & Computer Engineering Department Head at the United States Air Force Academy. “I look forward to seeing this become a standard part of our curriculum.”
Moku:Go’s software was designed to appeal to a generation that is accustomed to intuitive user interfaces and broad compatibility. Liquid Instruments is bringing the user experience out of the flip-phone era and has designed intuitive Windows and Mac interfaces that are inviting and powerful for students. It offers remote access capabilities and clearly diagrammed views of the signal processing chain, which makes it easy for students to learn difficult concepts whether they are in person or remote. The student-centric design ensures they are learning the core concepts, rather than just learning the equipment itself.
Not only does Moku:Go help increase student engagement, but incorporation into curriculum also reduces faculty and teaching assistant workloads. The platform supports Python, LabVIEW and MATLAB APIs and has published examples of MATLAB live scripts for remote instruction, live student assistance and plagiarism control.
Its robust feature set and sophisticated software can also unlock advanced capabilities for makers and even high school students looking to explore engineering. Whether they are learning the basics of resistors and op-amps or designing an advanced quadcopter with sensors and autonomous navigation, Moku:Go enables easier access to otherwise complex concepts and hands-on engineering projects anytime, anywhere at an affordable price.
Liquid Instruments is introducing Moku:Go for science and engineering students as part of its growing product portfolio of high-precision instrumentation solutions developed by its team of experimental physicists and engineers that know firsthand what is necessary to transform the way learning and research is performed at all levels. The existing product, Moku:Lab, has been utilized for years by top institutions worldwide, enabling breakthrough research in the areas of photonics, electronics, and materials science.
“Our first product, Moku:Lab, gave R&D scientists the power and flexibility they needed to do their job, all in a streamlined and cost-effective platform. Now with Moku:Go we will bring those same advantages to improve the overall quality of education and motivate students to study science and engineering,” said Professor Daniel Shaddock, CEO and co-founder of Liquid Instruments. “Students deserve lab equipment that is powerful and flexible, but also simple and fun to use. Improving access to critical educational tools will empower students from all walks of life to pursue a career in STEM.”
Moku:Go starts at $499 and can be customized to match school colors, with volume purchasing for educational institutions. For information on education discounts, accessories and full specifications, please visit the product page here .
For more information about Liquid Instruments and its full suite of products, please visit https://liquidinstruments.com .
About Liquid Instruments
Liquid Instruments is a leader in precision software-defined instrumentation and is revolutionizing the way that scientists, engineers, and students expand their knowledge and conduct research & development. Their product line of hardware and software solutions leverages the computational power of modern FPGAs to create highly customizable instrumentation for controlling experiments and acquiring and analyzing data. The team’s IP in software-defined hardware enables Moku products to be dynamically reconfigurable in the field, serving a wide range of ever-changing experimental and process control situations. Moku:Lab is used by hundreds of top R&D institutions worldwide, and brings 12+ high-value instruments together into a compact, intuitive device that has greatly streamlined experimental workflows. For more information, please visit https://liquidinstruments.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210323005031/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Consortium Led by Axelspace Selected for Japan’s Space Strategy Fund Project “Technology to Enhance Capability of Next Generation Earth Observation Satellites”30.3.2026 01:35:00 CEST | Press release
~ Creating Climate Solutions and New Market Opportunities through Source-Specific CO2 Emission and Uptake Monitoring via Satellite Constellation and Aircraft ~ Axelspace Corporation, Meisei Electric Co., Ltd., ANA HOLDINGS INC., and JIJ Inc. are pleased to announce that their jointly proposed technology development project has been selected for Japan Aerospace Exploration Agency (JAXA)’s Space Strategy Fund under the theme “Technology to Enhance Capability of Next Generation Earth Observation Satellites.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323044518/en/ Conceptual Diagram of the project. Under this Space Strategy Fund initiative, spectrometers will be newly developed and demonstrated in orbit. In the future, the project envisions the establishment of a satellite constellation capable of observations at different times of the day. Project Summary (Planned) Technology Development Theme: Technology to Enhance Cap
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom